Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

  • Coignard, Juliette
  • Beesley, Jonathan
  • O'Mara, Tracy A.
  • Diez Gibert, Orland
  • Lopez-Fernandez, Adrià
  • Dennis, Joe
  • Tyrer, Jonathan
  • Lush, Michael
Càncer de mama; Genètica del càncer; Factors de risc, Cáncer de mama; Genética del cáncer; Factores de riesgo, Breast cancer; Cancer genetics; Risk factors, Breast cancer (BC) risk for BRCA1 and BRCA2 mutation carriers varies by genetic and familial factors. About 50 common variants have been shown to modify BC risk for mutation carriers. All but three, were identified in general population studies. Other mutation carrier-specific susceptibility variants may exist but studies of mutation carriers have so far been underpowered. We conduct a novel case-only genome-wide association study comparing genotype frequencies between 60,212 general population BC cases and 13,007 cases with BRCA1 or BRCA2 mutations. We identify robust novel associations for 2 variants with BC for BRCA1 and 3 for BRCA2 mutation carriers, P < 10−8, at 5 loci, which are not associated with risk in the general population. They include rs60882887 at 11p11.2 where MADD, SP11 and EIF1, genes previously implicated in BC biology, are predicted as potential targets. These findings will contribute towards customising BC polygenic risk scores for BRCA1 and BRCA2 mutation carriers.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The Spectrum of FANCM Protein Truncating Variants in European Breast Cancer Cases

  • Figlioli, Gisella
  • Kvist, Anders
  • Tham, Emma
  • Soukupova, Jana
  • Kleiblova, Petra
  • Muranen, Taru A
  • Balmaña Gelpí, Judith
  • Diez Gibert, Orland
Predisposició al càncer de mama; Factors de risc de càncer de mama; Espectre de mutació, Predisposición al cáncer de mama; Factores de riesgo de cáncer de mama; Espectro de mutación, Breast cancer predisposition; Breast cancer risk factors; Mutation spectrum, Germline protein truncating variants (PTVs) in the FANCM gene have been associated with a 2–4-fold increased breast cancer risk in case-control studies conducted in different European populations. However, the distribution and the frequency of FANCM PTVs in Europe have never been investigated. In the present study, we collected the data of 114 European female breast cancer cases with FANCM PTVs ascertained in 20 centers from 13 European countries. We identified 27 different FANCM PTVs. The p.Gln1701* PTV is the most common PTV in Northern Europe with a maximum frequency in Finland and a lower relative frequency in Southern Europe. On the contrary, p.Arg1931* seems to be the most common PTV in Southern Europe. We also showed that p.Arg658*, the third most common PTV, is more frequent in Central Europe, and p.Gln498Thrfs*7 is probably a founder variant from Lithuania. Of the 23 rare or unique FANCM PTVs, 15 have not been previously reported. We provide here the initial spectrum of FANCM PTVs in European breast cancer cases., This research was partially funded by Associazione Italiana Ricerca sul Cancro (AIRC; IG2015 no.16732) to P. Peterlongo, a fellowship from Fondazione Umberto Veronesi to G. Figlioli and by the Italian Ministry of Health with Ricerca Corrente and 5x1000 funds. E. Tham is supported by Region Stockholm (ALF). The Czech study was supported by a grant of the Ministry of Health of the Czech Republic NV16-29959A. CNIO study was partially supported by projects PI16/00440 and PI19/00640, supported by the Instituto de Salud Carlos III, cofunded by European Regional Development Fund (ERDF), the Spanish Network on Rare Diseases (CIBERER) and BRIDGES project H2020. Financial support for GENESIS resource and genotyping was provided by the Ligue Nationale contre le Cancer (grants PRE05/DSL, PRE07/DSL, PRE11/NA), the French National Institute of Cancer (INCa grant No b2008-029/LL-LC) and the comprehensive cancer center SiRIC, (Site de Recherche Intégrée sur le Cancer: Grant INCa-DGOS-4654). HEBCS was funded by Helsinki University Hospital Research Fund, Sigrid Juselius Foundation, The cancer Society of Finland. A.Vega is supported by the Spanish Health Research Foundation, Instituto de Salud Carlos III (ISCIII) through Research Activity Intensification Program (contract grant numbers: INT15/00070, INT16/00154, INT17/00133), and through Centro de Investigación Biomédica en Red de Enferemdades Raras CIBERER (ACCI 2016: ER17P1AC7112/2018); Autonomous Government of Galicia (Consolidation and structuring program: IN607B), and by the Fundación Mutua Madrileña (call 2018). This work was supported by the Australian National Health and Medical Research Council (APP1029974 and APP1074383) and by a Victorian Life Sciences Computation Initiative grant (number VR0182) on its Peak Computing Facility, an initiative of the Victorian Government. T.N-D is a Career Development Fellow of the National Breast Cancer Foundation (Australia, ECF-17-001). M.C.S. is a National Health and Medical Research Council (Australia) Senior Research Fellow. The Hungarian Breast and Ovarian Cancer Study was supported by Hungarian Research Grants KTIA-OTKA CK-80745 and NKFI OTKA K-112228 to E. Olah. Lithuanian study was supported by The Research Council of Lithuania grant SEN18/2015 and P-MIP-20-25 to R. Janavicius. The ICO was supported by the Carlos III National Health Institute funded by FEDER funds—a way to build Europe—[PI16/00563, PI19/00553 and CIBERONC]; the Government of Catalonia [Pla estratègic de recerca i innovació en salut (PERIS) Project MedPerCan, 2017SGR1282 and 2017SGR496]; and CERCA program.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Targeting OGG1 arrests cancer cell proliferation by inducing replication stress

  • Visnes, Torkild|||0000-0003-1047-988X
  • Benítez-Buelga, Carlos
  • Cázares-Körner, A.
  • Sanjiv, K.
  • Hanna, Bishoy
  • Mortusewicz, O.
  • Rajagopal, Veera M.|||0000-0002-5236-168X
  • Albers, J. J.
  • Hagey, D. W.
  • Bekkhus, T.
  • Eshtad, S.
  • Baquero, Juan Miguel|||0000-0002-6488-7742
  • Masuyer, G.
  • Wallner, Olov|||0000-0002-6481-237X
  • Müller, S.
  • Pham, T.
  • Göktürk, C.
  • Rasti, A.
  • Suman, S.
  • Torres, Raul|||0000-0001-9606-0398
  • Sarno, A.
  • Wiita, E.
  • Homan, E. J.
  • Karsten, S.
  • Marimuthu, K.
  • Michel, M.
  • Koolmeister, T.
  • Scobie, M.
  • Loseva, O.
  • Almlöf, I.
  • Unterlass, J. E.
  • Pettke, A.
  • Boström, J.
  • Pandey, M.
  • Gad, H.
  • Herr, P.
  • Jemth, A. S.
  • El Andaloussi, S.
  • Kalderén, C.
  • Rodriguez-Perales, Sandra|||0000-0001-7221-3636
  • Benítez, J.
  • Krokan, H. E.
  • Altun, M.
  • Stenmark, P.
  • Berglund, U. W.
  • Helleday, Thomas|||0000-0002-7384-092X
Altered oncogene expression in cancer cells causes loss of redox homeostasis resulting in oxidative DNA damage, e.g. 8-oxoguanine (8-oxoG), repaired by base excision repair (BER). PARP1 coordinates BER and relies on the upstream 8-oxoguanine-DNA glycosylase (OGG1) to recognise and excise 8-oxoG. Here we hypothesize that OGG1 may represent an attractive target to exploit reactive oxygen species (ROS) elevation in cancer. Although OGG1 depletion is well tolerated in non-transformed cells, we report here that OGG1 depletion obstructs A3 T-cell lymphoblastic acute leukemia growth in vitro and in vivo, validating OGG1 as a potential anti-cancer target. In line with this hypothesis, we show that OGG1 inhibitors (OGG1i) target a wide range of cancer cells, with a favourable therapeutic index compared to non-transformed cells. Mechanistically, OGG1i and shRNA depletion cause S-phase DNA damage, replication stress and proliferation arrest or cell death, representing a novel mechanistic approach to target cancer. This study adds OGG1 to the list of BER factors, e.g. PARP1, as potential targets for cancer treatment.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Small molecule inhibitor of OGG1 blocks oxidative DNA damage repair at telomeres and potentiates methotrexate anticancer effects

  • Baquero, Juan Miguel|||0000-0002-6488-7742
  • Benítez-Buelga, Carlos
  • Rajagopal, Varshni
  • Zhenjun, Zhao
  • Torres, Raul|||0000-0001-9606-0398
  • Müller, Sarah
  • Hanna, Bishoy M. F.|||0000-0001-7027-6553
  • Loseva, Olga
  • Wallner, Olov|||0000-0002-6481-237X
  • Michel, Maurice|||0000-0003-3261-2493
  • Rodriguez-Perales, Sandra|||0000-0001-7221-3636
  • Gad, Helge|||0000-0001-6530-1443
  • Visnes, Torkild|||0000-0003-1047-988X
  • Helleday, Thomas|||0000-0002-7384-092X
  • Benitez, Javier|||0000-0002-0923-7202
  • Osorio, Ana|||0000-0001-8124-3984
The most common oxidative DNA lesion is 8-oxoguanine which is mainly recognized and excised by the 8-oxoG DNA glycosylase 1 (OGG1), initiating the base excision repair (BER) pathway. Telomeres are particularly sensitive to oxidative stress (OS) which disrupts telomere homeostasis triggering genome instability. In the present study, we have investigated the effects of inactivating BER in OS conditions, by using a specific inhibitor of OGG1 (TH5487). We have found that in OS conditions, TH5487 blocks BER initiation at telomeres causing an accumulation of oxidized bases, that is correlated with telomere losses, micronuclei formation and mild proliferation defects. Moreover, the antimetabolite methotrexate synergizes with TH5487 through induction of intracellular reactive oxygen species (ROS) formation, which potentiates TH5487-mediated telomere and genome instability. Our findings demonstrate that OGG1 is required to protect telomeres from OS and present OGG1 inhibitors as a tool to induce oxidative DNA damage at telomeres, with the potential for developing new combination therapies for cancer treatment.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Pot1 and damage response malfunction trigger acquisition of somatic activating mutations in the vegf pathway in cardiac angiosarcomas

  • Calvete, Oriol|||0000-0002-2623-2876
  • García-Pavía, Pablo|||0000-0002-5470-2257
  • Domınguez, Fernando|||0000-0001-8408-363X
  • Mosteiro, Lluc|||0000-0003-4041-9706
  • Perez Cabornero, Lucía|||0000-0002-2605-9006
  • Cantalapiedra, Diego
  • Zorio, Esther|||0000-0003-3608-4210
  • Ramon y Cajal, Teresa|||0000-0003-3490-3585
  • Crespo-Leiro, Maria Generosa|||0000-0002-3085-167X
  • Teule, Alex|||0000-0003-0028-7200
  • Lázaro García, Conxi|||0000-0002-7198-5906
  • Morente, Manuel M.|||0000-0001-6004-330X
  • Urioste, Miguel|||0000-0001-7583-7305
  • Benitez, Javier|||0000-0002-0923-7202
Mutations in the POT1 gene explain abnormally long telomeres and multiple tumors including cardiac angiosarcomas (CAS). However, the link between long telomeres and tumorigenesis is poorly understood. Here, we have studied the somatic landscape of 3 different angiosarcoma patients with mutations in the POT1 gene to further investigate this tumorigenesis process. In addition, the genetic landscape of 7 CAS patients without mutations in the POT1 gene has been studied. Patients with CAS and nonfunctional POT1 did not repress ATR (ataxia telangiectasia RAD3-related)-dependent DNA damage signaling and showed a constitutive increase of cell cycle arrest and somatic activating mutations in the VEGF (vascular endothelial growth factor)/angiogenesis pathway (KDR gene). The same observation was made in POT1 mutation carriers with tumors different from CAS and also in CAS patients without mutations in the POT1 gene but with mutations in other genes involved in DNA damage signaling. Inhibition of POT1 function and damage-response malfunction activated DNA damage signaling and increased cell cycle arrest as well as interfered with apoptosis, which would permit acquisition of somatic mutations in the VEGF/angiogenesis pathway that drives tumor formation. Therapies based on the inhibition of damage signaling in asymptomatic carriers may diminish defects on cell cycle arrest and thus prevent the apoptosis deregulation that leads to the acquisition of driver mutations.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

  • Coignard, Juliette
  • Beesley, Jonathan
  • O'Mara, Tracy A.
  • Diez Gibert, Orland
  • Lopez Fernandez, Adrià
  • Dennis, Joe
  • Tyrer, Jonathan
  • Lush, Michael
Càncer de mama; Genètica del càncer; Factors de risc, Cáncer de mama; Genética del cáncer; Factores de riesgo, Breast cancer; Cancer genetics; Risk factors, Breast cancer (BC) risk for BRCA1 and BRCA2 mutation carriers varies by genetic and familial factors. About 50 common variants have been shown to modify BC risk for mutation carriers. All but three, were identified in general population studies. Other mutation carrier-specific susceptibility variants may exist but studies of mutation carriers have so far been underpowered. We conduct a novel case-only genome-wide association study comparing genotype frequencies between 60,212 general population BC cases and 13,007 cases with BRCA1 or BRCA2 mutations. We identify robust novel associations for 2 variants with BC for BRCA1 and 3 for BRCA2 mutation carriers, P < 10−8, at 5 loci, which are not associated with risk in the general population. They include rs60882887 at 11p11.2 where MADD, SP11 and EIF1, genes previously implicated in BC biology, are predicted as potential targets. These findings will contribute towards customising BC polygenic risk scores for BRCA1 and BRCA2 mutation carriers.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

The Spectrum of FANCM Protein Truncating Variants in European Breast Cancer Cases

  • Figlioli, Gisella
  • Kvist, Anders
  • Tham, Emma
  • Soukupova, Jana
  • Kleiblova, Petra
  • Muranen, Taru A
  • Balmaña Gelpí, Judith
  • Diez Gibert, Orland
Predisposició al càncer de mama; Factors de risc de càncer de mama; Espectre de mutació, Predisposición al cáncer de mama; Factores de riesgo de cáncer de mama; Espectro de mutación, Breast cancer predisposition; Breast cancer risk factors; Mutation spectrum, Germline protein truncating variants (PTVs) in the FANCM gene have been associated with a 2–4-fold increased breast cancer risk in case-control studies conducted in different European populations. However, the distribution and the frequency of FANCM PTVs in Europe have never been investigated. In the present study, we collected the data of 114 European female breast cancer cases with FANCM PTVs ascertained in 20 centers from 13 European countries. We identified 27 different FANCM PTVs. The p.Gln1701* PTV is the most common PTV in Northern Europe with a maximum frequency in Finland and a lower relative frequency in Southern Europe. On the contrary, p.Arg1931* seems to be the most common PTV in Southern Europe. We also showed that p.Arg658*, the third most common PTV, is more frequent in Central Europe, and p.Gln498Thrfs*7 is probably a founder variant from Lithuania. Of the 23 rare or unique FANCM PTVs, 15 have not been previously reported. We provide here the initial spectrum of FANCM PTVs in European breast cancer cases., This research was partially funded by Associazione Italiana Ricerca sul Cancro (AIRC; IG2015 no.16732) to P. Peterlongo, a fellowship from Fondazione Umberto Veronesi to G. Figlioli and by the Italian Ministry of Health with Ricerca Corrente and 5x1000 funds. E. Tham is supported by Region Stockholm (ALF). The Czech study was supported by a grant of the Ministry of Health of the Czech Republic NV16-29959A. CNIO study was partially supported by projects PI16/00440 and PI19/00640, supported by the Instituto de Salud Carlos III, cofunded by European Regional Development Fund (ERDF), the Spanish Network on Rare Diseases (CIBERER) and BRIDGES project H2020. Financial support for GENESIS resource and genotyping was provided by the Ligue Nationale contre le Cancer (grants PRE05/DSL, PRE07/DSL, PRE11/NA), the French National Institute of Cancer (INCa grant No b2008-029/LL-LC) and the comprehensive cancer center SiRIC, (Site de Recherche Intégrée sur le Cancer: Grant INCa-DGOS-4654). HEBCS was funded by Helsinki University Hospital Research Fund, Sigrid Juselius Foundation, The cancer Society of Finland. A.Vega is supported by the Spanish Health Research Foundation, Instituto de Salud Carlos III (ISCIII) through Research Activity Intensification Program (contract grant numbers: INT15/00070, INT16/00154, INT17/00133), and through Centro de Investigación Biomédica en Red de Enferemdades Raras CIBERER (ACCI 2016: ER17P1AC7112/2018); Autonomous Government of Galicia (Consolidation and structuring program: IN607B), and by the Fundación Mutua Madrileña (call 2018). This work was supported by the Australian National Health and Medical Research Council (APP1029974 and APP1074383) and by a Victorian Life Sciences Computation Initiative grant (number VR0182) on its Peak Computing Facility, an initiative of the Victorian Government. T.N-D is a Career Development Fellow of the National Breast Cancer Foundation (Australia, ECF-17-001). M.C.S. is a National Health and Medical Research Council (Australia) Senior Research Fellow. The Hungarian Breast and Ovarian Cancer Study was supported by Hungarian Research Grants KTIA-OTKA CK-80745 and NKFI OTKA K-112228 to E. Olah. Lithuanian study was supported by The Research Council of Lithuania grant SEN18/2015 and P-MIP-20-25 to R. Janavicius. The ICO was supported by the Carlos III National Health Institute funded by FEDER funds—a way to build Europe—[PI16/00563, PI19/00553 and CIBERONC]; the Government of Catalonia [Pla estratègic de recerca i innovació en salut (PERIS) Project MedPerCan, 2017SGR1282 and 2017SGR496]; and CERCA program.